Changes in Beneficial Ownership · 4

Rani Therapeutics Holdings, Inc.

RANINASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jul 23, 2026Accepted Jul 23, 2026, 4:10 PM EDTFiling CIK 1856725Accession 0001031686-26-000006

View company →Permanent SEC source ↗

Structured filing — 4

form4-07232026_040701.xml

Open full document ↗

Filing details

Report period: 2026-07-21
Issuer: Rani Therapeutics Holdings, Inc.
Issuer CIK: 0001856725
Trading symbol: RANI

Reporting owner 1

Name: IMRAN MIR A
Reporting owner CIK: 0001031686
Relationship: Director · 10% owner
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE, CA, 95131

Non-derivative transactions

Non-derivative transactions · 1 reported row
Security	Transaction date	Code	Amount	A / D	Price (USD)	Owned after	Ownership
Class A Common Stock	2026-07-21	P · Form 4	36,000	A	0.69^[F1]	2,119,334	D

Table key

P · Form 4: Purchase on the market or privately
A: Acquired
D: Direct

Non-derivative holdings

Non-derivative holdings · 2 reported rows
Security	Amount owned	Ownership	Nature of ownership
Class A Common Stock	74,139	I	See footnote^[F2]
Class B Common Stock	22,660,053	I	See footnote^[F3]

Table key

I: Indirect

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.688 to $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.↩ 1
F2: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.↩ 1
F3: The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 Class B Shares held by InCube Labs, LLC and 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.↩ 1

Signature 1

Signed: /s/ Mir A Imran
Date: 2026-07-23

Company context

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® Capsule™, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® Capsule technology.

Current securities

RANINASDAQ · EQUITY · Current

Get the free weekly BCS email.